2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead
Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
About the Author
